Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Friday, May 29, 2026
Outlook’s $5 Million Registered Direct Offering
Thursday, May 28, 2026
VERAXA’s $27 Million Debt Financing
Medicus’s $22 Million Non-Dilutive Financing
Polaryx’s $10 Million Private Placement
Psilera’s $8 Million Seed Round
Medicenna’s $3 Million Public Offering
Wednesday, May 27, 2026
Apogee’s $1.3 Billion Strategic Financing
Q32’s $55 Million Private Placement
ClearNote’s $52 Million Series D
Secretome’s $30 Million Series A
Protuoso’s $9 Million Seed Round
BLEEDnFIRE’s Non-Dilutive Financing
Tuesday, May 26, 2026
Editas’s $319 Million Public Offering…More
Cartesian’s $150 Million Non-Dilutive Financing
Rani’s $20 Million Registered Direct Offering
MindMaze’s $10 Million Equity Investment
Friday, May 22, 2026
Assembly’s $100 Million Public Offering
NervGen’s $60 Million Public Offering
BioStem’s $2 Million Private Placement
Thursday, May 21, 2026
Immix’s $150 Million Public Offering
Nanobiotix’s $99 Million Public Offering
Akari’s $5 Million Private Placement
HCW’s $4 Million Private Placement
Synakis’s $2 Million Pre-Seed Round
Jupiter’s $2 Million Registered Direct Offering
Wednesday, May 20, 2026
Annovis’s $15 Million Public Offering…More
AIM’s $2 Million Registered Direct Offering and Private Placement
Resverlogix’s $2 Million Private Placement
PreveCeutical’s $1 Million Private Placement
Lilly’s Acquisition of Engage Bio
Tuesday, May 19, 2026
Relay’s $175 Million Public Offering
Forlong’s $17 Million Series Pre-B
Blank Bio’s $7 Million Seed Round
GeoVax’s $3 Million Private Placement
InMed’s Merger with Mentari Therapeutics
Monday, May 18, 2026
Quince’s $187 Million Private Placement and Acquisition of Orphai
Gossamer’s $120 Million Debt Financing
Rein’s $57 Million Public Offering
Neurocrine’s Acquisition of Soleno Therapeutics
Friday, May 15, 2026
Ocugen’s $130 Million Debt Financing…More
NanoViricides’s $2 Million Registered Direct Offering
Silexion’s $1 Million Warrant Exercise
Thursday, May 14, 2026
Gilead’s $3 Billion Debt Financing
CREATE’s $122 Million Series B
XORTX’s $5 Million Public Offering
Biogen’s Acquisition of Apellis Pharmaceuticals
Wednesday, May 13, 2026
UroMems’s $60 Million Equity Investment
Lantern’s $9 Million Registered Direct Offering
CEL-SCI’s $7 Million Public Offering
Tuesday, May 12, 2026
Isomorphic’s $2.1 Billion Series B
Aquestive’s $150 Million Debt Financing
Cerevance’s $20 Million Series C
Infex’s $6 Million Venture Financing
Tevogen’s $3 Million Private Placement
Friday, May 8, 2026
Cytokinetics’ $805 Million Public Offering…More
Artiva’s $300 Million Public Offering
Pharvaris’s $115 Million Public Offering
AIM’s $4 Million Warrant Exercise
Thursday, May 7, 2026
Angelini’s $4 Billion Acquisition of Catalyst…More
Travere’s $475 Million Debt Financing…More
Viridian’s $350 Million Public Offerings…More
Odyssey’s $279 Million IPO…More
Anagram’s $250 Million Equity Investment
ParcelBio’s $13 Million Seed Round
Wednesday, May 6, 2026
Avalo’s $375 Million Public Offering
CellCentric’s $220 Million Series D
InflaRx’s $150 Million Public Offering
LTZ’s $38 Million Venture Financing
Signadori’s $13 Million Seed Round
Cytokinetics’s Public Offering
Tuesday, May 5, 2026
Aura’s $299 Million Public Offering…More, More
Cellectar’s $140 Million Private Placement
Lexicon’s $100 Million Debt Financing
Cytospire’s $83 Million Series A
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.